UC San Diego Health Moores Cancer Center | Strategic Alliance Partners

Pembrolizumab inspired a 70% risk reduction in women with mismatch repair–deficient advanced endometrial cancer and a 46% risk reduction in patients with mismatch repair–proficient disease.

The growing availability of biomarkers has led to the advent of more targeted therapies such as the antibody-drug conjugates (ADCs) fam-trastuzumab deruxtecan-nxki, ado-trastuzumab emtansine, and sacituzumab govitecan-hziy.

Whether administered as an immune primer or concurrently with extended field chemoradiation, atezolizumab demonstrated efficacy in triggering T-cell clonal expansions and prolonging progression-free survival in patients with cervical cancer.

Researchers are using biomarker-testing to determine which patients with lung cancer might benefit from PARP inhibitors.

Understanding the implications of age and gender upon safety and efficacy outcomes in patients with renal cell carcinoma is critical to the delivery of individualized care.